KZR Key Statistics, Chart & Performance
The current stock price of KZR is 6.34 USD. In the past month the price increased by 2.26%. In the past year, price decreased by -4.52%.
KZR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About KZR
Company Profile
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2018-06-21. The firm's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The firm is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
Company Info
KEZAR LIFE SCIENCES INC
4000 Shoreline Ct Ste 300
South San Francisco CALIFORNIA 94080 US
CEO: John Fowler
Employees: 55
Phone: 16508225600
KEZAR LIFE SCIENCES INC / KZR FAQ
What does KZR do?
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company is headquartered in South San Francisco, California and currently employs 55 full-time employees. The company went IPO on 2018-06-21. The firm's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The firm is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
What is the stock price of KEZAR LIFE SCIENCES INC today?
The current stock price of KZR is 6.34 USD.
Does KZR stock pay dividends?
KZR does not pay a dividend.
What is the ChartMill rating of KEZAR LIFE SCIENCES INC stock?
KZR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is KZR stock listed?
KZR stock is listed on the Nasdaq exchange.
What is the Short Interest ratio of KEZAR LIFE SCIENCES INC (KZR) stock?
The outstanding short interest for KEZAR LIFE SCIENCES INC (KZR) is 3.87% of its float.
KZR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KZR. When comparing the yearly performance of all stocks, KZR is one of the better performing stocks in the market, outperforming 90.24% of all stocks.
KZR Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KZR. While KZR seems to be doing ok healthwise, there are quite some concerns on its profitability.
KZR Financial Highlights
Over the last trailing twelve months KZR reported a non-GAAP Earnings per Share(EPS) of -8.44. The EPS increased by 5.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.55% | ||
| ROE | -77.93% | ||
| Debt/Equity | 0.03 |